MGMT and Thrombocytopenia: Patients experiencing thrombocytopenia grade 0–2 had higher levels of MGMT at baseline (median 14.5 Fm μg−1, range 3.1–52.5 Fm μg−1) and after CISTEM treatment (median 5.5 Fm μg−1, range 0.6–31.3 Fm μg−1) than patients with grade 3 toxicity (median 6.7 Fm μg−1, range 2.8–15.9 Fm μg−1 at baseline; P=0.0158; and median 2.2 Fm μg−1, range 0.4–7.8 Fm μg−1 at day 5; P=0.0123; Figure 2).